Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia.

在患有 X 连锁无丙种球蛋白血症的患者中 ， 用雷米西韦和中和抗体混合物治疗 SARS - CoV - 2 复发。

• 影响指数: 12.074
• 发表时间: Sep 2021
• 来源期刊: Int J Infect Dis
• DOI: 10.1016/j.ijid.2021.07.064
• PMID: 34332085
• 文章类型: Case Reports
• 中科院分区: Q2
• 方向: 医学
• 作者列表: Palomba E,Carrabba M,Zuglian G,Alagna L,Saltini P,Fortina V,Hu C,Bandera A,Fabio G,Gori A,Muscatello A

关键词: COVID-19; Casirivimab; Imdevimab; Immunocompromised; Monoclonal antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA

Mesh: Adenosine Monophosphate / analogs & derivatives; Adult; Agammaglobulinemia; Alanine / analogs & derivatives; Antibodies, Neutralizing; Antibodies, Viral; COVID-19 / drug therapy; Genetic Diseases, X-Linked; Humans; Recurrence; SARS-CoV-2

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.

摘要

在2019年冠状病毒病（COVID-19）大流行期间，体液免疫缺陷患者发生慢性感染的风险较高,且转归为阴性.关于该人群的治疗选择的数据很少。此病例报告讨论了在患有X连锁无丙种球蛋白血症的成年患者中，使用remdesivir和单克隆抗体治疗疾病复发。